Ademi LLP is investigating NextCure for possible breaches of fiduciary duty related to its merger with Avere Therapeutics. The deal leaves NextCure shareholders with about 1.21% ownership in the combined company and a contingent right to proceeds from certain asset sales, while Avere shareholders hold 98.79%. Concerns include substantial benefits to NextCure insiders and restrictive terms limiting competing bids. The investigation focuses on whether NextCure's board acted in shareholders' best interests during the transaction.
The global electric vehicle (EV) market is projected to grow annually by 9.0%, reaching a value of $2.74 trillion in 2026, driven by regulatory changes, expanded charging infrastructure, and battery supply-chain development. Key growth areas include ...
Revenium has successfully completed a SOC 2 Type II audit conducted by AuditOne LLP, confirming the security, availability, and confidentiality controls of its AI cost and spend management platform. This certification is crucial as enterprises increa...
Lyora Therapeutics, a biotech startup, has launched with $2.5 million in seed funding to develop genetic medicines targeting inherited retinal diseases that currently lack treatments. Their lead programs, LYA-101 and LYA-102, aim to treat retinitis p...
Flex secured $70 million in a Series B1 funding round led by Halo Fund to accelerate the launch of Flex Global, an AI-native private banking platform serving high-net-worth business owners in over 100 countries. The platform integrates multi-currency...
Fanatics Studios and DICK’S Sporting Goods’ Cookie Jar & a Dream Studios are producing a documentary about Olympic gymnast Suni Lee. The film offers an intimate look at her life, focusing on her comeback after battling chronic kidney disease and comp...
